Skip to main content
SpringerLink
Log in

Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Objective

To evaluate the antitumor effects of miriplatin-lipidol suspension and emulsion.

Materials and methods

Fifty rabbits with VX2 liver tumors were randomly assigned to ten groups. Then, we prepared four types of mixtures: a suspension of lipiodol and miriplatin (ML), an emulsion of miriplatin dissolved with lipiodol and contrast medium (MLC) or saline (MLS), and saline alone (S). Ratios between lipiodol and contrast medium/saline volumes were 1:1/4, 1:1/2, 1:1, and 1:2 respectively. We used the same dose of miriplatin (2 mg/kg) and lipiodol (0.1 ml/kg) in each emulsion and suspension group. After intra-arterial infusion, the tumor growth rate was calculated, and sequential change of the plasma platinum concentration, the platinum concentration in the tumor and in surrounding normal liver tissue was also measured.

Results

Among the ten groups, the tumor growth rate was lower in MLC and MLS groups, and the difference between tumor treated with MLS emulsion (ratio 1:1/2) and ML suspension was significant (p = 0.02). The platinum concentration in the normal liver tissue was lower in MLS and MLC groups than in the ML group, and that in the tumor was higher in the MLS and MLC emulsion (ratio 1:1/2) groups.

Conclusion

We suggest that miriplatin-lipiodol emulsion may be more effective than suspension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  PubMed  Google Scholar 

  2. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72:505–16.

    Article  PubMed  Google Scholar 

  3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.

    Article  PubMed  CAS  Google Scholar 

  4. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008;7(3):237–57.

    PubMed  Google Scholar 

  5. Achenbach T, Seifert JK, Pitton MB, Schunk K, Junginger T. Chemoembolization for primary liver cancer. Eur J Surg Oncol. 2002;28(1):37–41.

    Article  PubMed  CAS  Google Scholar 

  6. Yamamoto K, Shimizu T, Narabayashi I. Intra-arterial infusion chemotherapy with lipiodol-CDDP suspension for hepatocellular carcinoma. Cardiovasc Interv Radiol. 2000;23:26–39.

    Article  CAS  Google Scholar 

  7. Shimamura Y, Gunven P, Takenaka Y, Shimizu H, Shima Y, Akimoto H, et al. Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE). Cancer. 1988;61:238–42.

    Article  PubMed  CAS  Google Scholar 

  8. Kobayashi S, Narimatsu Y, Ogawa K, Hashimoto S, Nakatsuka S, Miura H, et al. Transcatheter hepatic arterial chemoembolization using epirubicin–lipiodol: experimental and pharmacological evaluation. Cancer Chemother. Pharmacol. 1992; 31(Suppl.):S45–50.

    Google Scholar 

  9. Ohnishi K, Sugita S, Nomura F, Iida S, Tanabe Y. Arterial chemoembolization with mitomycin C microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma. Am J Gastroenterol. 1987;82:876–9.

    PubMed  CAS  Google Scholar 

  10. Okusaka T, Okuda S, Ueno H, Ikeda M, Iwata R, Furukawa H, et al. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 2002;62:228–33.

    Article  PubMed  CAS  Google Scholar 

  11. Kasai K, Ushio A, Sawara K, Miyamoto Y, kasai Y, Oikawa K, et al. Transcatheter arterial chemoembolization with a fine powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol. 2010;16(27):3437–44.

    Article  PubMed  CAS  Google Scholar 

  12. Maeda H, Uchida NA, Sasaki T. Liposoluble platinum (II) complexes with antitumor activity. Jpn J Cancer Res. 1986;77:523–5.

    PubMed  CAS  Google Scholar 

  13. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull. 2000;23:344–8.

    Article  PubMed  CAS  Google Scholar 

  14. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473–83.

    Article  PubMed  CAS  Google Scholar 

  15. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci. 2009;100:189–94.

    Article  PubMed  CAS  Google Scholar 

  16. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs. 2004;22:169–76.

    Article  PubMed  CAS  Google Scholar 

  17. Ikeda K, Okusaka T, Ikeda M, Morimoto M. Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355 (miriplatin hydrate). Safety and efficacy in combination with embolizing agents. Gan to kagaku ryoho. 2010;37(2):271–5.

    PubMed  Google Scholar 

  18. Fujiyama S, Shibata J, Maeda S, Tanaka M, Noumaru S, Sato K, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer. 2003;89:1614–9.

    Article  PubMed  CAS  Google Scholar 

  19. Ueda T, Murata S, Mine T, Onozawa S, Onda M, Naito Z, et al. Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. Sci World J. Epub 2012; p 7. doi:10.1100/2012/961986 (Article ID 961986).

  20. Haaga JR, Exner AA, Wang Y, Stowe NT, Tarcha PJ. Combined tumor therapy by using radiofrequency ablation and 5-FU-laden polymer implants: evaluation in rats and rabbits. Radiology. 2005;237(3):911–8.

    Article  PubMed  Google Scholar 

  21. Yamashita Y, Taketomi A, Itoh S, Harimoto N, Morita K, Fukuhara T, et al. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call) in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2010;65:301–7.

    Article  PubMed  CAS  Google Scholar 

  22. Yamashita Y, Nakagawa N, Miyawaki M. Experimental study of hepatic arterial embolization therapy by various formulations of anti-cancer agent lipiodol. Nippon Acta Radiol. 1985;45(10):1313–21.

    PubMed  CAS  Google Scholar 

  23. de Baere T, Zhang X, Aubert B, Harry G, Lagrange C, Ropers J, et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology. 1996;201:731–5.

    PubMed  Google Scholar 

  24. Demachi H, Matsui O, Abo H, Tatsu H. Simulation model based on non-Newtonian fluid mechanics applied to the evaluation of the embolic effect of emulsions of iodized oil and anticancer drug. Cardiovasc Intervent Radiol. 2000;23:285–90.

    Article  PubMed  CAS  Google Scholar 

  25. Luo FR, Yen TY, Wyrck SD, Chaney SG. High performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J Chromatogr B. 1999;724:345–56.

    Article  CAS  Google Scholar 

  26. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31:269–80.

    Article  PubMed  Google Scholar 

  27. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.

    Article  PubMed  Google Scholar 

  28. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  PubMed  CAS  Google Scholar 

  29. Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, et al. Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update. Hepatol Res. 2012;42(6):523–42.

    Article  PubMed  CAS  Google Scholar 

  30. Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol. 2012;42:175–82.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Radiology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu City, Shiga, 520-2192, Japan

    Yuki Tomozawa, Norihisa Nitta, Shinji Ohta, Hideji Otani, Shobu Watanabe, Akinaga Sonoda, Keiko Tsuchiya, Ayumi Nitta-Seko, Masashi Takahashi & Kiyoshi Murata

Authors
  1. Yuki Tomozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norihisa Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinji Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideji Otani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shobu Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akinaga Sonoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keiko Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ayumi Nitta-Seko
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masashi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kiyoshi Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuki Tomozawa.

About this article

Cite this article

Tomozawa, Y., Nitta, N., Ohta, S. et al. Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model. Jpn J Radiol 31, 662–667 (2013). https://doi.org/10.1007/s11604-013-0231-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-013-0231-7

Keywords

Search

Navigation